Parkinson’s Disease Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.67 Billion
CAGR (2026-2031)	7.56%
Fastest Growing Segment	MAO-B inhibitors
Largest Market	North America
Market Size (2031)	USD 8.78 Billion

Market Overview

The Global Parkinson’s Disease Drugs Market will grow from USD 5.67 Billion in 2025 to USD 8.78 Billion by 2031 at a 7.56% CAGR. Parkinson’s disease drugs are pharmaceutical agents such as levodopa and dopamine agonists designed to manage neurodegenerative symptoms by restoring dopamine levels. The market is primarily driven by an aging global population and rising disease prevalence which creates sustained demand for prolonged symptom management. Additionally robust clinical pipelines and increased research funding serve as critical catalysts for sector development. According to the Parkinson’s Foundation, in 2024, approximately 10 million individuals globally were living with Parkinson’s disease, underscoring the urgent necessity for therapeutic advancements.

However the market faces a significant challenge due to the patent expiration of blockbuster drugs which triggers the influx of inexpensive generic alternatives. This competitive pressure erodes revenue for branded manufacturers and forces a strategic pivot toward expensive treatments that often encounter stringent reimbursement hurdles. Consequently the resulting pricing erosion diminishes the potential return on investment for innovative drug discovery thereby impeding overall market value expansion.

Key Market Drivers

Rising Prevalence of Parkinson’s Disease Globally acts as a primary catalyst for market expansion, fundamentally driven by the synchronous relationship between aging demographics and increased neurodegenerative diagnoses. As the global population life expectancy rises, the accumulation of patient cases creates a compounding demand for sustained pharmacological interventions, necessitating higher volumes of levodopa and dopamine agonists to manage debilitating motor symptoms. This escalating healthcare load is financially quantifiable; according to Parkinson Canada, 2024, in the 'Economic Burden Summary Report', the total cost associated with Parkinson’s disease in Canada was estimated to reach $3.3 billion for the year 2024. This substantial economic footprint indicates a critical, growing necessity for scalable therapeutic solutions, thereby ensuring consistent revenue streams for pharmaceutical developers addressing this expanding patient base.

Robust Clinical Pipeline of Disease-Modifying Therapies serves as the second vital driver, stimulating market value through the aggressive development of treatments that target underlying pathology rather than mere symptom management. The sector is witnessing a strategic pivot toward assets addressing alpha-synuclein and inflammation, supported by high levels of clinical activity and corporate investment. According to Cure Parkinson’s, July 2024, in the 'Clinical Trial Pipeline 2024 Update', there were 136 active clinical trials registering specifically for Parkinson’s disease therapeutics as of January 2024. This high volume of research activity often triggers major consolidation events that validate market potential; according to AbbVie, in August 2024, the company completed its strategic acquisition of Cerevel Therapeutics for approximately $8.7 billion, significantly bolstering its neuroscience portfolio and underscoring the high financial stakes involved in bringing next-generation therapies to market.

Download Free Sample Report

Key Market Challenges

The patent expiration of blockbuster drugs serves as a critical impediment to the revenue growth of the Global Parkinson’s Disease Drugs Market. When market exclusivity periods end, the sector experiences an immediate influx of generic formulations that are priced significantly lower than their branded counterparts. This transition creates intense competitive pressure, forcing branded manufacturers to lower prices or surrender market share. The resulting pricing erosion sharply reduces the overall monetary value of the market, as the revenue generated per prescription drops precipitously compared to the period of patent protection.

This market contraction is further accelerated by the financial strain the disease places on healthcare systems, which incentivizes the adoption of these lower-cost alternatives. According to the Parkinson’s Foundation, in 2025, the economic burden of Parkinson’s disease in the U.S. alone was estimated to reach nearly $61.5 billion. Faced with such escalating costs, insurance payers and government health programs aggressively mandate the use of generic substitutes to maintain fiscal sustainability. This systemic prioritization of cost-containment limits the adoption of higher-priced branded therapies, thereby directly restricting the financial expansion of the global market.

Key Market Trends

The Adoption of Continuous Subcutaneous Infusion Systems is rapidly altering the treatment landscape for advanced Parkinson’s disease by addressing the limitations of oral levodopa formulations. As the disease progresses, patients frequently experience motor fluctuations and "off" episodes due to the short half-life of oral medications, necessitating delivery mechanisms that ensure stable plasma drug concentrations. This trend focuses on pump-based technologies that provide continuous drug delivery to minimize symptom variability, offering a non-surgical alternative to deep brain stimulation. A significant market milestone occurred when regulators validated this modality's efficacy in stabilizing motor control. According to Supernus Pharmaceuticals, February 2025, in the 'Supernus Announces FDA Approval of ONAPGO' press release, the U.S. Food and Drug Administration approved the device as the first and only subcutaneous apomorphine infusion system specifically indicated for the continuous treatment of motor fluctuations in Parkinson's disease.

Simultaneously, the market is undergoing a structural Transition from Symptomatic Management to Disease-Modifying Therapies, driven by breakthroughs in regenerative medicine and cell replacement strategies. Unlike traditional dopamine replacement agents that merely mask symptoms, these novel interventions aim to restore lost neural circuitry by implanting functional dopaminergic neurons. This shift represents a move toward restorative care, distinguishing itself from earlier pipeline focuses on protein aggregation or inflammation. Recent long-term data has bolstered confidence in the durability of these cellular interventions. According to BlueRock Therapeutics, October 2025, in the 'BlueRock Therapeutics reports positive 36-month results' announcement, the high-dose cohort in the Phase I trial of the investigational cell therapy bemdaneprocel demonstrated a mean reduction of 4.3 points in the MDS-UPDRS Part II score from baseline, indicating sustained improvement in motor experiences of daily living.

Segmental Insights

The MAO-B inhibitors segment is positioned as the fastest-growing category within the Global Parkinson’s Disease Drugs Market because of the rising preference for combination therapies that extend the efficacy of levodopa. This growth is primarily driven by the ability of these drugs to manage motor fluctuations and significantly reduce off-episodes in patients with advanced disease stages. Furthermore, recent approvals of novel therapeutics by regulatory bodies like the US FDA have improved treatment options, encouraging widespread clinical adoption. Consequently, the capacity of MAO-B inhibitors to maintain dopamine levels effectively supports their rapid expansion in the global marketplace.

Regional Insights

North America maintains a leading position in the Global Parkinson’s Disease Drugs Market due to the high prevalence of neurodegenerative disorders and a well-structured healthcare system. The United States contributes significantly to this dominance through substantial investments in pharmaceutical research and development. Market expansion is further supported by favorable reimbursement frameworks that improve patient access to medication. Additionally, the proactive role of the US Food and Drug Administration in accelerating drug approvals encourages continuous innovation. These factors, combined with the strong presence of key industry players, ensure the region remains the primary revenue generator globally.

Recent Developments

• In February 2025, Supernus Pharmaceuticals, Inc. announced that the U.S. FDA had approved Onapgo, an apomorphine infusion device for the continuous treatment of motor fluctuations in adults with advanced Parkinson’s disease. Previously known as SPN-830, this drug-device combination was designed to offer a non-invasive alternative to surgical treatments by delivering consistent medication levels to reduce "off" episodes. The approval followed a successful resubmission of the company's New Drug Application, which addressed prior regulatory queries regarding product quality and the device's master file. The company prepared to make the treatment available to patients in the second quarter of the year.
• In October 2024, AbbVie Inc. received approval from the U.S. FDA for Vyalev, a levodopa-based therapy for adults with advanced Parkinson’s disease. This treatment became the first subcutaneous 24-hour continuous infusion system approved for managing motor fluctuations in patients whose symptoms were not adequately controlled by oral medications. The regulatory decision was based on data from a pivotal Phase 3 study evaluating the efficacy of the continuous infusion compared to oral immediate-release carbidopa/levodopa. The results indicated that patients treated with the new therapy experienced superior improvement in "on" time without troublesome dyskinesia.
• In August 2024, Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved its new treatment for Parkinson’s disease, marketed as Crexont. This novel oral formulation of carbidopa and levodopa extended-release capsules was developed to improve the duration of "Good On" time for patients, offering more consistent symptom management with less frequent dosing compared to immediate-release options. The regulatory approval was supported by results from the pivotal Phase 3 RISE-PD clinical trial, which demonstrated statistically significant improvements in daily motor fluctuation control. The company planned to launch the product commercially in the United States shortly after receiving the clearance.
• In March 2024, NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, announced the publication of positive results from its pivotal Phase 3 BouNDless trial in a leading medical journal. The study evaluated the efficacy and safety of ND0612, a continuous, 24-hour subcutaneous infusion of liquid levodopa/carbidopa, in patients with Parkinson’s disease experiencing motor fluctuations. The research demonstrated that the investigational treatment met its primary endpoint, showing a statistically significant increase in "on" time without troublesome dyskinesia compared to oral immediate-release levodopa/carbidopa. These findings highlighted the potential of the therapy to address the limitations of oral medications for patients with advancing disease.

Key Market Players

• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• GSK plc
• Teva Pharmaceuticals Industries Ltd
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Kissei Pharmaceutical Co., Ltd.
• AstraZeneca Plc
• Eli Lilly and Company
• Newron Pharmaceuticals SPA

By Mechanism of Action	By Distribution Channel	By Region
Dopamine Agonists Anticholinergic MAO-B Inhibitors Amantadine Carbidopa-levodopa COMT Inhibitors Other Mechanisms of Action	Retail Pharmacies Hospital Pharmacies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Parkinson’s Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Parkinson’s Disease Drugs Market, By Mechanism of Action:

• Dopamine Agonists
• Anticholinergic
• MAO-B Inhibitors
• Amantadine
• Carbidopa-levodopa
• COMT Inhibitors
• Other Mechanisms of Action

• Parkinson’s Disease Drugs Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Others

• Parkinson’s Disease Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE